Eradicating deadly staph using a new breed of antibiotics has revealed promising results in research released by QUT, to help overcome one of the biggest modern medical challenges.
The bacteria attach to medical devices including catheters, artificial joints, implants and patients’ burns and wounds, establishing bacterial biofilms, a leading cause of failing antibiotic therapies and chronic infections.
QUT researchers have developed hybrid antibiotics designed to penetrate the slimy shield protecting invasive golden staph (Staphylococcus aureus) infections.
Led by Associate Professor Makrina Totsika and PhD student Anthony Verderosa (pictured below), the research has been published in top infectious diseases journal Antimicrobial Agents and Chemotherapy.
The study found hybrid antibiotics worked well by destroying Staph biofilms grown in the lab.
“Biofilms are a sticky, slimy coating that often prevents conventional antibiotics from accessing bacterial cells,” Mr Verderosa said.
“We have developed a new breed of antibiotic that tricks biofilms into releasing their protected cells allowing access through the protective slimy coating of the biofilm.
“This allows for the biofilms to be eradicated.”
He said the microscopic compound emits a fluorescence signal enabling researchers to watch the drug penetrating the biofilm, either killing the bacteria directly or leaving them susceptible to killing.
Associate Professor Totsika said the majority of infections, even those not associated with an implanted medical device, involve biofilms in some way so the potential for these drugs is wide.
“We are now gearing up to do pre-clinical testing,” she said.
“What is promising is the fact that our compounds are hybrids of drugs that are already in clinical use as stand-alone therapies, such as conventional antibiotics and nitroxides, so this offers hope that they could be translated into clinical therapies in the not so distant future.”
Hospital acquired infections and increasing resistance to antibiotics has challenged medical researchers to find and test novel antimicrobial agents, including alternatives to antibiotics.
The World Health Organisation has identified antibiotic resistant pathogens as one of the “biggest threats to global health today”.
Associate Professor Totsika said there was scope to apply the research beyond medicine, to agriculture, biotechnology and other industries.
Go deeper with Bing News on:
- Phoenix Instinct AI Powered Smart Wheelchair Wins Toyota Mobility Challengeon January 20, 2021 at 11:02 am
Toyota Mobility Foundation, in partnership with Nesta Challenges, announces the winner of $4 million global Mobility Unlimited Challenge in virtual event.
- STU ELLIS: Try something different this timeon January 19, 2021 at 8:35 pm
It was a year ago when the White House and China announced they had an agreement to end the tariff war, and that China would buy $72 billion worth of ...
- Cell Bag Bioreactor Chamber Market Overview By Share, Size, Industry Players, Revenue And Product Demand Forecast Till 2027on January 19, 2021 at 1:57 pm
The report titled "Cell Bag Bioreactor Chamber Market Outlook: Global Demand Analysis & Opportunity Outlook 2027" delivers detailed overview of the global cell bag bioreactor chamber market in terms ...
- Bacterial Type I Signal Peptidases as Antibiotic Targetson January 9, 2021 at 3:59 pm
The arrow indicates the point of cleavage and P1 and P3 residues are in bold. ‡A hybrid protein made up of signal peptide of outer membrane protein A from Escherichia coli and the nuclease A ...
- Chemo Drug Potentially More Potent than Remdesivir Against Coronaviruson January 5, 2021 at 12:13 pm
Two of the drugs, pralatrexate, a chemotherapy, and azithromycin, an antibiotic, were successful at preventing ... “We have demonstrated the value of our novel hybrid approach that combines ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- MRSA bacterial infection outbreak declared over at QEH's Unit 3on January 20, 2021 at 1:52 pm
A bacterial infection outbreak that had restricted visits to a unit of the Queen Elizabeth Hospital since the first week of January appears to be over.
- APM Stock: 9 Things to Know About Aptorum as Shares Fly on Staph Infection Drug Newson January 20, 2021 at 9:32 am
Stock Market News, Stock Advice & Trading Tips Aptorum (NASDAQ:APM) stock is on the rise Wednesday after announcing approval ...
- Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus ...on January 20, 2021 at 8:00 am
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies i ...
- Stock Alert: Aptorum Up 30% On Clearance To Initiate Phase 1 Trial Of ALS-4 In Canadaon January 20, 2021 at 7:35 am
(RTTNews) - Shares of Aptorum Group Ltd. (APM) jumped over 30% on Wednesday morning after the company received clearance from Canada health regulator to commence a phase 1 trial of ALS-4 for ...
- APM Stock: Aptorum Group Gains On Phase 1 Study Newson January 20, 2021 at 6:03 am
APM stock is screaming for the top, squeezing the shorts after announcing an approval to begin a Phase 1 clinical trial.